395 completed. 395 Phase 1, 47 Phase 2.
By phase and status
Follow Respiratory Hypersensitivity: new trials by email Literature Review of Respiratory Hypersensitivity trials Research Report on Respiratory Hypersensitivity
Trials (filtered) newest first · largest first
All 395 trials
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix .
Trial Phase Status Sponsor Enrollment Start Updated
A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma Budesonide/formoterol fumarate Aerosphere, Budesonide/formoterol fumarate pMDI - Asthma Phase 1 Completed 16 2026-03-05 2026-07-15 Bioequivalence Study of AJU-R713 and R713R in Healthy Adult Volunteers AJU-R713, R713R - Bronchial Asthma, Perennial Allergic Rhinitis Phase 1 Completed 62 2025-12-12 2026-09-18 Phase I Study of PollenVax in Patients With Mugwort Pollen-Induced Allergic Rhinitis PollenVax, Placebo - Rhinitis Allergic Phase 1 Completed 30 2025-11-22 2026-06-29 A Clinical Study to Evaluate SM17 in Healthy Participants SM17, SM17 placebo - Atopic Dermatitis, Asthma Phase 1 Completed 30 2025-10-14 2026-04-06 A Study of Inhaled AZD8630 in Adolescents With Asthma AZD8630, Dry powder inhaler - Asthma Phase 1 Completed 10 2025-06-11 2025-10-14 A Study to Evaluate the Safety and Tolerability of Multiple Dose of IBI3002 in Healthy and Asthmatic Participants Placebo, IBI3002 - Asthma Phase 1 Completed 44 2025-05-14 2026-06-09 Study on the Safety, Tolerability, and Pharmacokinetics of PA9159 Nasal Spray in Healthy Adult Subjects PA9159 nasal spray solution, 80 μg one day treatment, PA9159 nasal spray solution, 160 μg one day treatment, PA9159 nasal spray solution, 320 μg one day treatment - Allergic Rhinitis Phase 1 Completed 36 2025-03-14 2026-01-15 A Study to Assess the Potential for Airway Sensitivity Reactions With Propellants HFA-152a (Test) and HFA-134a (Reference) Administered Via Pressurized Inhalers in Adults With Mild Asthma HFA-152A propellant, HFA-134A propellant - Asthma Phase 1 Completed 20 2025-03-11 2026-08-21 Study to Evaluate the Pharmacokinetics and Pharmacodynamics of AZD4604 Given Via the Turbuhaler® Device in Adults With Mild Asthma. AZD4604, Placebo, Genuair - Asthma Phase 1 Completed 28 2025-02-27 2025-06-05 Serum sST2/ miR-223 as a Dual Biomarker for Disease Activity & Clinical Efficacy of SLIT in HDM-Induced Allergic Rhinitis Sublingual Immunotherapy (SLIT) containing HDM extracts - HDM-Induced Allergic Rhinitis Phase 1 Completed 54 2025-02-01 2026-02-27 A Safety, Pharmacokinetic, and Pharmacodynamic Study of Once Daily Inhaled AZD8630 in Adults With Asthma AZD8630, Placebo, Saphira device - Asthma Phase 1 Completed 24 2025-01-28 2025-10-03 A Study to Investigate the Exposure of Budesonide, Glycopyrronium, and Formoterol (BGF) Delivered by Hydrofluoroolefin (HFO) Propellant Metered Dose Inhaler (MDI) Compared to a Hydrofluoroalkane (HFA) Propellant MDI in Healthy Adults Treatment A: BGF MDI HFO, Treatment B: BGF MDI HFA - Healthy Participants Phase 1 Completed 105 2025-01-23 2025-06-05 A Clinical Trial for Evaluation of Efficacy, Safety and Immunogenicity of GNR-127 (Recombinant ABP Antigen Protein Which Carries a Birch Pollen Allergen [BET V 1] and an Apple Allergen [MAL D 1]) in Patients With Birch Pollen Allergic Rhinitis. GNR-127, 20 mcg, GNR-127, 40 mcg, GNR-127, 80 mcg - Rhinitis, Allergic, Seasonal Phase 1 / Phase 2 Completed 150 2024-10-07 2026-09-21 A Study to Investigate the Relative Bioavailability of AZD8630 Following a Device and Formulation Transition in Healthy Participants. AZD8630 (test formulation) via test inhaler, AZD8630 (reference formulation) via Monodose inhaler, Test inhaler - Healthy Participants Phase 1 Completed 32 2024-08-06 2024-10-17 Study of the Effect of HFA-152a and HFA-134a Propellants on Mucociliary Clearance in Healthy Participants HFA-152a, HFA-134a, Radiolabeled saline solution - Asthma Phase 1 Completed 24 2024-07-29 2026-04-14 Safety, Tolerability, and Pharmacokinetics of PA9159 Inhalation Aerosol in Healthy Adult Subjects PA9159 Inhalation aerosol, 60 μg one day treatment, PA9159 Inhalation aerosol, 120 μg one day treatment, PA9159 Inhalation aerosol, 240 μg one day treatment - Bronchial Asthma Phase 1 Completed 40 2024-07-22 2025-12-30 A Study to Compare the Pharmacokinetics (PK) of Salbutamol Administered Via Metered Dose Inhalers (MDI) Containing Propellants HFA-152A (Test) or HFA-134A (Reference) in Healthy Participants Aged 18 to 55 Inclusive Salbutamol HFA-152a, Salbutamol HFA-134a - Asthma, Healthy Participants Phase 1 Completed 60 2024-06-04 2026-01-12 Pharmacokinetic Profile and Safety of Fluticasone Propionate and Albuterol Sulfate in Combination When Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Children Aged 4 to 11 Years Old TEV-56248, Fp MDPI - Asthma Phase 1 Completed 30 2024-05-16 2026-08-04 A Study to Investigate Relative Bioavailability of Two Different Dosage Forms for Tozorakimab Via Subcutaneous Administration in Healthy Volunteers Tozorakimab - Healthy Participants Phase 1 Completed 46 2024-04-08 2024-09-19 Effect of Halotherapy in Children With Asthma Halotherapy (Salt Therapy) - Therapy, Oxygen Inhalation Phase 1 Completed 70 2024-03-06 2024-08-02
Showing 20 of 395. Sign in to see all of them.
Narrower conditions Asthma (312) · Rhinitis, Allergic (61) · Pulmonary Disease, Chronic Obstructive (39) · Rhinitis, Allergic, Seasonal (31) · Hypersensitivity (24) · Rhinitis, Allergic, Perennial (15) · Dermatitis, Atopic (9) · Inflammation (6) · Rhinitis (5) · Urticaria (4) · Cystic Fibrosis (3) · Dust Mite Allergy (3) · Immune System Diseases (3) · Nasal Obstruction (3) · Obesity (3)
Broader conditions Hypersensitivity, Immediate (395) · Immune System Diseases (392) · Respiratory Tract Diseases (392) · Hypersensitivity (371) · Bronchial Diseases (313) · Lung Diseases, Obstructive (312) · Lung Diseases (311) · Nose Diseases (95) · Otorhinolaryngologic Diseases (95) · Rhinitis (90) · Pathological Conditions, Signs and Symptoms (58) · Pathologic Processes (49) · Chronic Disease (40) · Disease Attributes (40)
Interventions Budesonide (23) · Fluticasone (17) · montelukast (11) · Charcoal (10) · Formoterol Fumarate (8) · Albuterol (7) · Budesonide, Formoterol Fumarate Drug Combination (6) · Fluticasone-Salmeterol Drug Combination (6) · Salmeterol Xinafoate (6) · Sodium Chloride (6) · fluticasone furoate (6) · Injections, Subcutaneous (5) · Omalizumab (5) · Prednisone (5) · Beclomethasone (4)
Sponsors GlaxoSmithKline (62) · AstraZeneca (37) · Orion Corporation, Orion Pharma (13) · Merck Sharp & Dohme LLC (11) · Chiesi Farmaceutici S.p.A. (8) · MedImmune LLC (8) · University of North Carolina, Chapel Hill (8) · Boehringer Ingelheim (7) · National Institute of Allergy and Infectious Diseases (NIAID) (7) · Intech Biopharm Ltd. (6) · Pfizer (6) · Teva Branded Pharmaceutical Products R&D, Inc. (6) · Novartis Pharmaceuticals (5) · Stallergenes Greer (5) · Novartis (4)
Countries United States (112) · United Kingdom (75) · Germany (48) · Australia (28) · China (24) · Canada (13) · Finland (11) · New Zealand (9) · South Korea (9) · Belgium (8) · Netherlands (8) · Sweden (6) · Taiwan (6) · Russia (5) · Austria (4)
Top investigators Robert Wood, MD (5) · Cecil Charles, PhD (3) · David B Peden, MD, MS (3) · Leena Mattila, MD, PhD (3) · Ulla Sairanen, MSc (3)
Results publications PMID 24184147 , PMID 19001265 , PMID 22464647 , PMID 19680119 , PMID 22726593 , PMID 23374268 , PMID 24035151 , PMID 32907575 , PMID 40185989 , PMID 10831441 , PMID 11069570 , PMID 11163535 , PMID 11297958 , PMID 11468003 , PMID 11728816 , PMID 15379842 , PMID 16553814 , PMID 17083353 , PMID 17717202 , PMID 18244953 , PMID 19446146 , PMID 19647862 , PMID 19717725 , PMID 19821718 , PMID 19944580 , PMID 20921983 , PMID 20976161 , PMID 21057005 , PMID 21639872 , PMID 21642470 , PMID 21725898 , PMID 21729182 , PMID 22393898 , PMID 22544892 , PMID 22616628 , PMID 22621776 , PMID 22955319 , PMID 22989372 , PMID 23102735 , PMID 23176889 , PMID 23181790 , PMID 23706713 , PMID 23725004 , PMID 24093504 , PMID 24105252 , PMID 24261946 , PMID 24439076 , PMID 24568613 , PMID 24846652 , PMID 24934402
NIH funding 2016 (8) , 2014 (6) , 2015 (5) , 2019 (4) , 2009 (3) , 2018 (3) , P01AT002620 (2) , P01HL158507 (2) , U19AI095261 (2) , 2017 (1) , 2023 (1) , P01AT002647 (1) , P50AT002782 (1) , U19AI077437 (1)